Reuters logo
BRIEF-Ocera Therapeutics says OCR-002 prevents progression of fibrosis in non-alcoholic fatty liver disease
April 12, 2017 / 8:21 PM / 5 months ago

BRIEF-Ocera Therapeutics says OCR-002 prevents progression of fibrosis in non-alcoholic fatty liver disease

April 12 (Reuters) - Ocera Therapeutics Inc-

* Ocera Therapeutics announces presentation of data showing ocr-002 prevented progression of fibrosis in preclinical model of non-alcoholic fatty liver disease (nafld)

* Data supports potential for ocr-002 in treatment of non-alcoholic fatty liver disease

* Ocera Therapeutics - nafld rats treated with ocr-002 showed significant reduction in progression of fibrosis compared to untreated nafld rats Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below